IN THE HIGH COURT OF JUDICATURE AT MADRAS
RMT. TEEKAA RAMAN, J.
M/s. Dharma Pharmacy Pvt. Ltd., Tamil Nadu, Rep. by its Director, V. Dharmalingam & Others - Appellant
Versus
The State of Tamil Nadu, Rep. by T. Gowri, Drugs Inspector, Chennai & Another - Respondent
Crl.O.P. Nos. 4847 of 2017 & 27548 of 2016 & Crl.M.P. Nos. 14062 & 14063 of 2016 & 3620 & 3621 of 2017
Decided On : 12-08-2022
Drugs and Magic Remedies - Advertisement of UTRAVIT-Syrup 200 ml - Drugs and Magic Remedies (Objectionable Advertisement) Act, 1954, Section 3(c), Section 3(d) r/w.S1.Nos.12, 13 and 18 - The court discussed the jurisdiction of Drugs Inspectors under the Special Act, the power to issue show cause notices, and the competence to launch prosecution for contravention of the Special Act. The court also highlighted the ban on certain words in advertisements and the need for regulation of online advertisements of drugs and medicinal tablets under the Special Act.
Fact of the Case:
An objectionable advertisement for UTRAVIT-Syrup 200 ml was published in a magazine, leading to a prosecution under the Drugs and Magic Remedies (Objectionable Advertisement) Act, 1954. The court considered the jurisdiction of Drugs Inspectors, issuance of show cause notices, and the competence to launch prosecution.
Finding of the Court:
The court found that the prosecution initiated by the Drugs Inspector under the Special Act was sustainable in law, despite the jurisdictional issues raised. The court also highlighted the need for regulation of online advertisements of drugs and medicinal tablets under the Special Act.
Issues: The issues involved the jurisdiction of Drugs Inspectors, the power to issue show cause notices, and the competence to launch prosecution for contravention of the Special Act.
Ratio Decidendi: The court held that the prosecution initiated by the Drugs Inspector under the Special Act was valid, emphasizing the need for regulation of online advertisements of drugs and medicinal tablets under the Special Act.
Final Decision: The court upheld the prosecution initiated by the Drugs Inspector under the Special Act and highlighted the necessity for regulating online advertisements of drugs and medicinal tablets under the Special Act.
JUDGMENT
(Prayer: This Criminal Original Petition is filed under Section 482 of Cr.P.C., to call for the records in C.C.No.6352 of 2016 on the file of the X Metropolitan Magistrate Court, Egmore, Chennai – 600 006 and quash the same.
This Criminal Original Petition is filed under Section 482 of Cr.P.C., to call for the records in C.C.No.2841 of 2016 on the file of the IV Metropolitan Magistrate Court, Saidapet, Chennai – 600 016 and quash the same.)
Common Order
1. As petitioners and the issue involved in both the Criminal Original Petitions viz., Crl.O.P.Nos.4847 of 2017 and 27548 of 2016 are one and the same, by consent, they were taken up together and the submissions of the learned counsel on either sides were heard.
2. The brief facts of the case are as follows:
(i) On September 2015, an advertisement has been published in the monthly magazine viz., “Health Choice”, Volume 8, Issue 9, Page 39 with respect of a drug “UTRAVIT-Syrup 200 ml” with the claim that the said drug is a remedy and cures “Menstrual disorders in women and Disease and Disorders of the uterus, Disorders of menstrual flows and Female diseases (in general)” “TAMIL” was noticed by the then Drugs Inspector within her jurisdiction, which is an objectionable advertisement as per Section 3(c) and Section 3(d) r/w.S1.Nos.12, 13 and 18 of the Schedule of Drugs and Magic Remedies (Objectionable Advertisement) Act, 1954 [hereinafter referred to as “Special Act”].
(ii) On 09.09.2015, a show cause memo was sent to the Editor, “Health Choice”, M/s.Dharma Publications, for publishing the said objectionable advertisement which is in contravention of
(1) Section 3 (c) of Drugs and Magic Remedies (Objectionable Advertisement) Act, 1954.
(2) Section 3 (d) read with the Schedule under Sl.No.12 of Drugs and Magic Remedies (Objectionable Advertisement) Act, 1954.
(3) Section 3 (d) read with the Schedule under Sl.No.13 of Drugs and Magic Remedies (Objectionable Advertisement) Act, 1954 and
(4) Section 3 (d) read with the Schedule under Sl.No.18 of Drugs and Magic Remedies (Objectionable Advertisement) Act, 1954, and the Editor was also requested to disclose the details of the advertising person.
(iii) A reply dated 15.10.2015 was received by the then Drugs Inspector, Arumbakkam Range i/c from the Editor, Health Choice, wherein, he has stated that the referred advertisement are all regarding Ayurvedic products which does not refer to any magic remedy or magic cure or has he tried to make a false claim or mislead to give a false impression regarding the true character of the products mentioned, but it referred only to the basic quality of the products and has not disclosed the details of the advertising person.
(iv) Thereafter, the then Drugs Inspector, Arumbakkam Range i/c. has sent a letter to the Director of Drugs Control, Tamil Nadu, requesting for the permission to investigate at the premises of Dharma Publications [publisher of Health Choice Magazine], to proceed further with this investigation.
(v) On 22.06.2016, the respondent inspected the premises of Dharma Publications. During inspection, the respondent handed over the Reminder III dated 22.06.2016 to the Editor, Health Choice Magazine requesting him to disclose the details of the advertising person. But he has refused to receive the Reminder III dated 22.06.2016 and also refused to give the written statement about the constitution of the company.
(vi) The respondent sent a show cause memo to the manufacturing company M/s.Dharma Pharmacy Pvt. Ltd., No.48, G.W.T. Road, opp. to Rajiv Gandhi Memorial, Sriperumbudhur – 602 105, Tamil Nadu, India, but received no reply. Further a reminder letter dated 19.07.2016 was also sent to above company, for which there was no reply either.
(vii) On 03.08.2016, the respondent submitted a detailed report to the Director of Drugs Control, Tamil Nadu Chennai-06 requesting to prosecute the petitioners and accordingly the sanction order was received on 29.08.2016 to prosecute
AI
The main legal point established is the validity of prosecution initiated by the Drugs Inspector under the Special Act and the need for regulation of online advertisements of drugs and medicinal tabl....
Drugs Inspectors under Section 8 of 1954 Act lack statutory power to file direct complaints; must forward to police for FIR as per Supreme Court directions; existing complaints quashed for procedural....
Sildenafil Citrate is an allopathic drug and it cannot be used by anybody else unless a person who holds licence for it.
Prohibition of manufacture and sale of certain drugs and cosmetics - Quashment of complaint - Very fact of selling this drug as one of ingredients in Ozomen capsule and not displaying name in prescri....
Unauthorised sale of drugs and violation of license conditions – Section 468 of Cr.P.C. is not applicable.
Point of Law : There is a blatant violation of the provisions of Rule 1945 and Act 1954. Rule 170 prohibits the advertisement of Ayurvedic, Sidda or Unani drugs without permission. Moreover Rule 170(....
The main legal point established in the judgment is that the inherent powers of the High Court should be exercised sparingly and with caution, and that the complaint disclosed a cognizable offence un....
Point of Law : As per Section 19 of the D.C. Act, the manufacturer can take the plea in respect of the test analysis.
Login now and unlock free premium legal research
Login to SupremeToday AI and access free legal analysis, AI highlights, and smart tools.
Login
now!
India’s Legal research and Law Firm App, Download now!
Copyright © 2023 Vikas Info Solution Pvt Ltd. All Rights Reserved.